A carregar...
Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies
Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-β (Aβ) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals. Aβ capture by these clinical antibodies is explained here with the...
Na minha lista:
| Publicado no: | Sci Rep |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4549621/ https://ncbi.nlm.nih.gov/pubmed/25880481 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep09649 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|